Complete Guide to Givosiran Pharmacokinetics
Overview
Givosiran is a siRNA used in the Rare Disease therapeutic area. It is indicated for Acute Hepatic Porphyria. Interactive PK/PD simulator for givosiran (Givlaari) in acute hepatic porphyria. Explore ALA reduction and dosing optimization.
Mechanism of Action
Givosiran exerts its pharmacological effect by targeting ALAS1. As a siRNA, it modulates this target to achieve therapeutic efficacy in Acute Hepatic Porphyria. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PK/PD models for Givosiran:
| Parameter | Value |
|---|---|
| ka | 0.308 h⁻¹ |
| CL F | 38.8 L/h (70kg) |
| Vc F | 26.3 L (70kg) |
| dose | 2.5 mg/kg SC monthly |
| IIV CL | 44.5% CV |
| IIV Vc | 67.2% CV |
| bioavailability | ~0.50 |
| protein binding | >90% |
| t half absorption | 2.25 h |
| t half elimination | ~6 h (plasma) |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Givosiran is administered via the SC route. Subcutaneous administration provides sustained absorption from the injection site. Bioavailability and absorption rate may vary by injection site and volume.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Rare Disease therapeutic area, for the treatment of Acute Hepatic Porphyria, understanding the pharmacokinetics of Givosiran is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Givosiran pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Givosiran PK Simulator
Explore Givosiran pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Givosiran?
The elimination half-life of Givosiran depends on patient-specific factors. Use our interactive Givosiran PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Givosiran administered?
Givosiran is administered via the SC route. It is indicated for Acute Hepatic Porphyria. As a siRNA, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Givosiran?
Key pharmacokinetic parameters for Givosiran include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Givosiran dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Givosiran PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.